We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
(+19%)
Cap. Flow
-$233M
Cap. Flow
% of AUM
-3.6%
Top 10 Holdings %
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alector
ALEC
|
+$249M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$112M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$71.9M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$58M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
+$53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$259M |
| 2 |
Biogen
BIIB
|
+$235M |
| 3 |
AGN
Allergan plc
AGN
|
+$128M |
| 4 |
CVS Health
CVS
|
+$52M |
| 5 |
Centene
CNC
|
+$48.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.53% |
| 2 | Financials | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
51
DELISTED
Apellis Pharmaceuticals
APLS
| $34.4M | 0.53% |
1,762,300
+1,435,300
| +439% | +$22.6M |
|
|
OBSV
52
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $33.3M | 0.52% |
2,605,531
| – | – |
|
53
Adicet Bio
ACET
$76.7M
| $32.9M | 0.51% |
43,128
| – | – |
|
54
Prothena Corp
PRTA
$443M
| $29.5M | 0.46% |
+2,435,278
| New | +$30.4M |
|
|
GNFT
55
DELISTED
Genfit
GNFT
| $29.5M | 0.46% |
+1,230,314
| New | +$28.4M |
|
56
Gilead Sciences
GILD
$166B
| $28.9M | 0.45% |
443,800
| – | – |
|
57
KALA BIO
KALA
$12.1M
| $28.5M | 0.44% |
1,381
| – | – |
|
58
Xtant Medical Holdings
XTNT
$57.7M
| $28.1M | 0.43% |
9,207,012
| – | – |
|
|
CELG
59
DELISTED
Celgene Corp
CELG
| $27.8M | 0.43% |
295,000
-2,961,700
| -91% | -$259M |
|
60
ProQR Therapeutics
PRQR
$246M
| $27.5M | 0.43% |
1,982,031
+544,300
| +38% | +$8.13M |
|
61
Heron Therapeutics
HRTX
$93.1M
| $26.1M | 0.4% |
1,069,000
-331,300
| -24% | -$8.67M |
|
62
CareDx
CDNA
$1.86B
| $26.1M | 0.4% |
+827,600
| New | +$24.1M |
|
|
ALPN
63
DELISTED
Alpine Immune Sciences Inc
ALPN
| $25.2M | 0.39% |
3,670,955
+372,439
| +11% | +$2.32M |
|
|
CBAY
64
DELISTED
Cymabay Therapeutics
CBAY
| $24.9M | 0.39% |
+1,874,955
| New | +$19.9M |
|
65
Corvus Pharmaceuticals
CRVS
$1.11B
| $24M | 0.37% |
5,967,584
| – | – |
|
66
Amgen
AMGN
$213B
| $23.2M | 0.36% |
122,100
| – | – |
|
|
HARP
67
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $23.2M | 0.36% |
+244,641
| New | +$32.2M |
|
68
Enanta Pharmaceuticals
ENTA
$361M
| $22.3M | 0.34% |
+233,100
| New | +$20.9M |
|
69
Natera
NTRA
$35.8B
| $22.2M | 0.34% |
1,077,586
+393,500
| +58% | +$6.16M |
|
70
PUT
BioMarin Pharmaceuticals
BMRN
$12B
| $22.2M | 0.34% |
+250,000
| New | +$23.2M |
|
71
Rhythm Pharmaceuticals
RYTM
$7.38B
| $21.6M | 0.33% |
787,300
-141,200
| -15% | -$4.06M |
|
|
72
Biogen
BIIB
$31.9B
| $20.7M | 0.32% |
87,700
-747,549
| -90% | -$235M |
|
73
Aurinia Pharmaceuticals
AUPH
$1.92B
| $20.5M | 0.32% |
+3,149,810
| New | +$20.9M |
|
74
CALL
Takeda Pharmaceutical
TAK
$56.6B
| $20.4M | 0.32% |
+1,000,000
| New | +$20.1M |
|
75
Assembly Biosciences
ASMB
$507M
| $19.6M | 0.3% |
83,010
| – | – |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q1 2019 Portfolio in Review
As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in Alector worth $247M.
- OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
- OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
- OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
- OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
- OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
- OrbiMed opened 25 new positions and closed 31 in Q1 2019.
- OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.
Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.